Analyst firms · Citigroup · ZTS

Citigroup ZTS price target and rating history

Zoetis Inc. (ZTS) · Health Care

Citigroup rates Zoetis Inc. (ZTS) Buy with a $145 price target, as of its latest action on Apr 15, 2026. It has published 3 rating actions on ZTS since December 2021, including 0 upgrades and 0 downgrades. Across 6 firms with a ZTS price target in the last 12 months, the median target is $135. Citigroup's $145 is 7% above that.

Current rating

Buy

Price target

$145

Median target, all firms

$135

Actions on ZTS

3

Citigroup price target on ZTS

Every Citigroup rating on ZTS

• Apr 15, 2026
  InitiateCitigroup starts coverage at Buy, price target $145
• Mar 9, 2022
  ReiterateCitigroup cuts its price target to $208 from $232, keeps Neutral
• Dec 20, 2021
  ReiterateCitigroup raises its price target to $232 from $184, keeps Neutral

How other firms rate ZTS

Each firm's latest rating and stated target in the last 12 months.

Questions about Citigroup and ZTS

What is Citigroup's price target for ZTS?

Citigroup's latest stated price target for Zoetis Inc. (ZTS) is $145, from its action on Apr 15, 2026.

What is Citigroup's rating on ZTS?

Citigroup rates ZTS Buy, a bullish rating, as of Apr 15, 2026.

When did Citigroup last change its view on ZTS?

On Apr 15, 2026, Citigroup starts coverage at Buy, price target $145.

How does Citigroup's ZTS target compare with other analysts?

Across 6 firms with a ZTS price target in the last 12 months, the median target is $135. Citigroup's $145 is 7% above that.

More ZTS rating histories

• Barclays3

All Citigroup ratingsZTS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.